Sterling Capital Management’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Sterling Capital Management's AVTX Position: Q3 2026 in Review
Sterling Capital Management increased its Avalo Therapeutics (AVTX) stake by 174% in Q3 2026, buying an estimated $15.7K and bringing the position to 1,343 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2188.
Sterling Capital Management first reported a position in AVTX in Q2 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Sterling Capital Management held 1,343 shares of Avalo Therapeutics worth $20.6K as of Q3 2026.
- Sterling Capital Management bought 853 Avalo Therapeutics shares in Q3 2026, an estimated $15.7K.
- Avalo Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2188 holding.
- Sterling Capital Management first reported a position in Avalo Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.